Characteristics of patients who completed MOLST forms greater than 30 days before death vs patients who completed the forms within 30 days of death or never
| . | MOLST completed >30 d before death n = 118 (%) . | MOLST never completed or completed within 30 d of death n = 228 (%) . | P . |
|---|---|---|---|
| Age at diagnosis in years, median (IQR) | 73.5 (16) | 67 (16.5) | <.0001 |
| Age at diagnosis in years, n (%) | .0002 | ||
| ≥70 y | 78 (66.1) | 101 (44.3) | |
| <70 y | 39 (33.9) | 127 (55.7) | |
| Race, n (%) | .18 | ||
| White | 106 (90.7) | 194 (85.1) | |
| Black or other (Asian, Hispanic, other) | 11 (9.3) | 34 (14.9) | |
| ECOG-PS before death, n (%)* | .25 | ||
| 0 | 3 (4.3) | 4 (3.5) | |
| 1 | 6 (8.6) | 20 (17.5) | |
| ≥2 | 61 (87.1) | 90 (79.0) | |
| ECOG-PS at diagnosis, n (%)† | .21 | ||
| 0 | 11 (14.3) | 30 (24.6) | |
| 1 | 34 (44.2) | 45 (36.9) | |
| ≥2 | 32 (41.6) | 47 (38.6) | |
| Comorbidities, median n (IQR) | 4 (3) | 3 (2.5) | .01 |
| Comorbidities, n (%) | |||
| Hypertension | 68 (57.6) | 118 (51.8) | .31 |
| Hyperlipidemia | 45 (38.1) | 86 (37.7) | .99 |
| Diabetes | 27 (22.9) | 48 (21.1) | .68 |
| Chronic obstructive pulmonary disease | 24 (20.3) | 32 (14.0) | .17 |
| Coronary artery disease | 20 (17.0) | 38 (16.7) | .99 |
| Diagnosis | .12 | ||
| Acute myeloid leukemia | 72 (61.0) | 159 (69.7) | |
| Myelodysplastic syndrome | 46 (39.0) | 69 (30.3) | |
| Disease status at first hematology visit, n (%) | .66 | ||
| New diagnosis | 71 (60.2) | 148 (64.9) | |
| Relapsed disease/disease progression | 11 (9.3) | 18 (7.9) | |
| Other‡ | 36 (30.5) | 62 (27.2) | |
| Intent of care at first visit, n (%) | .03 | ||
| Curative | 10 (8.5) | 35 (15.4) | |
| Palliative | 61 (52.5) | 89 (38.6) | |
| Not stated | 46 (39.0) | 105 (46.1) | |
| Geographical location | .36 | ||
| Rural | 25 (21.2) | 59 (25.9) | |
| Urban | 93 (78.8) | 169 (74.1) | |
| . | MOLST completed >30 d before death n = 118 (%) . | MOLST never completed or completed within 30 d of death n = 228 (%) . | P . |
|---|---|---|---|
| Age at diagnosis in years, median (IQR) | 73.5 (16) | 67 (16.5) | <.0001 |
| Age at diagnosis in years, n (%) | .0002 | ||
| ≥70 y | 78 (66.1) | 101 (44.3) | |
| <70 y | 39 (33.9) | 127 (55.7) | |
| Race, n (%) | .18 | ||
| White | 106 (90.7) | 194 (85.1) | |
| Black or other (Asian, Hispanic, other) | 11 (9.3) | 34 (14.9) | |
| ECOG-PS before death, n (%)* | .25 | ||
| 0 | 3 (4.3) | 4 (3.5) | |
| 1 | 6 (8.6) | 20 (17.5) | |
| ≥2 | 61 (87.1) | 90 (79.0) | |
| ECOG-PS at diagnosis, n (%)† | .21 | ||
| 0 | 11 (14.3) | 30 (24.6) | |
| 1 | 34 (44.2) | 45 (36.9) | |
| ≥2 | 32 (41.6) | 47 (38.6) | |
| Comorbidities, median n (IQR) | 4 (3) | 3 (2.5) | .01 |
| Comorbidities, n (%) | |||
| Hypertension | 68 (57.6) | 118 (51.8) | .31 |
| Hyperlipidemia | 45 (38.1) | 86 (37.7) | .99 |
| Diabetes | 27 (22.9) | 48 (21.1) | .68 |
| Chronic obstructive pulmonary disease | 24 (20.3) | 32 (14.0) | .17 |
| Coronary artery disease | 20 (17.0) | 38 (16.7) | .99 |
| Diagnosis | .12 | ||
| Acute myeloid leukemia | 72 (61.0) | 159 (69.7) | |
| Myelodysplastic syndrome | 46 (39.0) | 69 (30.3) | |
| Disease status at first hematology visit, n (%) | .66 | ||
| New diagnosis | 71 (60.2) | 148 (64.9) | |
| Relapsed disease/disease progression | 11 (9.3) | 18 (7.9) | |
| Other‡ | 36 (30.5) | 62 (27.2) | |
| Intent of care at first visit, n (%) | .03 | ||
| Curative | 10 (8.5) | 35 (15.4) | |
| Palliative | 61 (52.5) | 89 (38.6) | |
| Not stated | 46 (39.0) | 105 (46.1) | |
| Geographical location | .36 | ||
| Rural | 25 (21.2) | 59 (25.9) | |
| Urban | 93 (78.8) | 169 (74.1) | |
AML, Acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group performance status; IQR, Interquartile range; MDS, Myelodysplastic syndrome.
162 patients did not have data for this variable in their medical record.
147 patients did not have data for this variable in their medical record.
Included patients who were transferring care, being evaluated for a second opinion, or their diagnosis was greater than 4 weeks after their initial visit.